Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.